These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29045554)

  • 21. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
    Ramalingam SS; Novello S; Guclu SZ; Bentsion D; Zvirbule Z; Szilasi M; Bernabe R; Syrigos K; Byers LA; Clingan P; Bar J; Vokes EE; Govindan R; Dunbar M; Ansell P; He L; Huang X; Sehgal V; Glasgow J; Bach BA; Mazieres J
    J Clin Oncol; 2021 Nov; 39(32):3633-3644. PubMed ID: 34436928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
    Stodtmann S; Eckert D; Joshi R; Nuthalapati S; Ratajczak CK; Menon R; Mensing S; Xiong H
    J Clin Pharmacol; 2022 Oct; 62(10):1236-1246. PubMed ID: 35403245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
    Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
    Wesolowski R; Stover DG; Lustberg MB; Shoben A; Zhao M; Mrozek E; Layman RM; Macrae E; Duan W; Zhang J; Hall N; Wright CL; Gillespie S; Berger M; Chalmers JJ; Carey A; Balasubramanian P; Miller BL; Amaya P; Andreopoulou E; Sparano J; Shapiro CL; Villalona-Calero MA; Geyer S; Chen A; Grever MR; Knopp MV; Ramaswamy B
    Oncologist; 2020 Aug; 25(8):e1158-e1169. PubMed ID: 32452601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of Platinum-free Interval and
    Puhalla SL; Diéras V; Arun BK; Kaufman B; Wildiers H; Han HS; Ayoub JP; Stearns V; Yuan Y; Helsten T; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak CK; Ramathal CY; Friedlander M
    Clin Cancer Res; 2021 Sep; 27(18):4983-4993. PubMed ID: 34131001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS; Olopade OI; DeMichele A; Yau C; van 't Veer LJ; Buxton MB; Hogarth M; Hylton NM; Paoloni M; Perlmutter J; Symmans WF; Yee D; Chien AJ; Wallace AM; Kaplan HG; Boughey JC; Haddad TC; Albain KS; Liu MC; Isaacs C; Khan QJ; Lang JE; Viscusi RK; Pusztai L; Moulder SL; Chui SY; Kemmer KA; Elias AD; Edmiston KK; Euhus DM; Haley BB; Nanda R; Northfelt DW; Tripathy D; Wood WC; Ewing C; Schwab R; Lyandres J; Davis SE; Hirst GL; Sanil A; Berry DA; Esserman LJ;
    N Engl J Med; 2016 Jul; 375(1):23-34. PubMed ID: 27406347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
    Byers LA; Bentsion D; Gans S; Penkov K; Son C; Sibille A; Owonikoko TK; Groen HJM; Gay CM; Fujimoto J; de Groot P; Dunbar M; Kang K; He L; Sehgal V; Glasgow J; Bach BA; Ellis PM
    Clin Cancer Res; 2021 Jul; 27(14):3884-3895. PubMed ID: 33947690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
    J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
    Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
    Middleton MR; Friedlander P; Hamid O; Daud A; Plummer R; Falotico N; Chyla B; Jiang F; McKeegan E; Mostafa NM; Zhu M; Qian J; McKee M; Luo Y; Giranda VL; McArthur GA
    Ann Oncol; 2015 Oct; 26(10):2173-9. PubMed ID: 26202595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
    Geyer CE; Sikov WM; Huober J; Rugo HS; Wolmark N; O'Shaughnessy J; Maag D; Untch M; Golshan M; Lorenzo JP; Metzger O; Dunbar M; Symmans WF; Rastogi P; Sohn JH; Young R; Wright GS; Harkness C; McIntyre K; Yardley D; Loibl S
    Ann Oncol; 2022 Apr; 33(4):384-394. PubMed ID: 35093516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
    Malhotra MK; Pahuja S; Kiesel BF; Appleman LJ; Ding F; Lin Y; Tawbi HA; Stoller RG; Lee JJ; Belani CP; Chen AP; Giranda VL; Shepherd SP; Emens LA; Ivy SP; Chu E; Beumer JH; Puhalla S
    Breast Cancer Res Treat; 2023 Apr; 198(3):487-498. PubMed ID: 36853577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.
    Nishio S; Takekuma M; Takeuchi S; Kawano K; Tsuda N; Tasaki K; Takahashi N; Abe M; Tanaka A; Nagasawa T; Shoji T; Xiong H; Nuthalapati S; Leahy T; Hashiba H; Kiriyama T; Komarnitsky P; Hirashima Y; Ushijima K
    Cancer Sci; 2017 Nov; 108(11):2213-2220. PubMed ID: 28837250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
    Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
    Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
    Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
    Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.